Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 65 years.
• People with an expected survival of at least 3 months.
• People diagnosed with aggressive non-Hodgkin's lymphoma (a type of blood cancer) whose disease has come back or stopped responding to at least one previous standard treatment, or whose cancer only partially responded after at least 4 cycles of treatment (with biopsy confirmation in certain cases).
• People who have at least one measurable area of disease visible on scans, meeting specific size requirements for the type of lesion.
• People whose general physical functioning falls within an acceptable range on a standard medical scale (rated 0–2 out of 5, meaning able to carry out daily activities with at most moderate limitations).
• People whose blood counts meet minimum levels for neutrophils (infection-fighting cells), platelets, and haemoglobin (with slightly lower thresholds allowed if the bone marrow is involved).
• People whose liver and kidney function test results are within acceptable ranges (with some flexibility if the lymphoma has affected the liver, or for people with a specific inherited condition called Gilbert's disease).

Who may not be able to join:

• People who have previously been treated with a chemotherapy drug called mitoxantrone or its liposomal form.
• People who have previously received doxorubicin or similar chemotherapy drugs (anthracyclines) where the total cumulative dose exceeds a specific limit.
• People who received any anti-cancer treatment — including chemotherapy, targeted therapy, steroids, or certain herbal medicines with anti-cancer effects — or participated in another clinical trial within 4 weeks (or 5 half-lives of the drug, whichever is earlier) before starting this trial.
• People who had a stem cell transplant using their own cells (autologous) or donor cells (allogeneic) within 100 days before the start of the trial.
• People who have previously received CAR-T cell therapy (a specialised immune cell treatment for cancer).
• People with a known allergy or sensitivity to any of the study drugs or their ingredients.
• People with uncontrolled ongoing illnesses such as active infections, uncontrolled high blood pressure, or uncontrolled diabetes.
• People with certain heart conditions, including abnormal heart rhythms, significant electrical conduction problems, heart failure classified as serious on a standard medical scale, reduced heart pumping function (ejection fraction below 50%), or a history of heart attack or severe heart disease within the past 6 months.
• People with active hepatitis B or hepatitis C infection, as defined by specific blood test results.
• People with HIV infection confirmed by a positive antibody test.
• People who have or have had another type of cancer in the past 5 years, except for certain low-risk skin cancers or early-stage cancers of the breast or cervix that have been effectively treated.
• People who are pregnant, breastfeeding, or of childbearing potential who are unwilling to use contraception during the trial.
• People with severe nerve damage or inflammation (grade 3 or higher on a medical severity scale).
• People with active lymphoma affecting the central nervous system (brain and spinal cord).
• People considered unsuitable for the trial by the treating doctor for any other reason.

Important: Always verify eligibility with the trial site directly before applying.